ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

India's Biocon Biologics in funding talks with Baring PE Asia

Country's largest biopharmaceutical eyes valuation of over $100m

Biocon Biologics offers treatment for chronic and acute diseases, including diabetes, oncology, nephrology and cancer.

NEW DELHI -- Biocon Biologics, a unit of India's largest biopharmaceutical company Biocon, is in talks with Asia-focused Baring Private Equity Asia to raise funding in lieu of a minority stake, sources familiar with the matter told DealStreetAsia.

While the exact size of the deal is unknown, it could be worth around $100 million or more, the sources said.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more